AbbVie Q4 revenue $16.6B (+10%); FY2025 adj EPS $10.00; guides FY2026 adj EPS $14.37-$14.57

AbbVie Inc.

2025-FY EPS reported $2.36 vs consensus $2.71 ▼ miss (-12.8%)

FY2025 revenue $61.160B (+8.6% reported); GAAP diluted EPS $2.36; adjusted diluted EPS $10.00 (-1.2% YoY).
Q4 revenue $16.618B (+10% reported); GAAP EPS $1.02; adjusted EPS $2.71; includes $0.71 IPR&D hit.
Immunology portfolio grew 14% in FY2025; Skyrizi $17.562B, Rinvoq $8.304B; Humira fell to $4.540B.
FY2026 adjusted EPS guidance $14.37-$14.57, excluding future IPR&D and milestones expense.
Announced voluntary pricing agreement with Trump admin; $100B U.S. R&D/capex over 10 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.